Mode
Text Size
Log in / Sign up

Bibliometric analysis identifies growing research trends and key hubs for short-chain fatty acids in cognitive impairmentMapping the Growing Research on Gut Health and Memory Loss Diseases

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that this bibliometric analysis maps research trends and does not provide clinical evidence for SCFA efficacy.

This systematic review performs a bibliometric analysis of literature records concerning short-chain fatty acids (SCFAs) and cognitive impairment. The scope includes an analysis of 425 publications from WoSCC and 514 from Scopus to identify research trends, key contributors, and emerging frontiers in the field.

The authors identify a continuous upward trend in publications from 2009 to 2025. Key findings include identifying China as the leading contributor of publications and Wenzhou Medical University as a core collaboration hub. High-frequency keywords identified include gut microbiota, Alzheimer's disease, neuroinflammation, and the gut-brain axis.

The analysis identifies research frontiers in drug therapy, microbiology, and chemistry. While the study maps the landscape of SCFA research and highlights areas for future investigation, it is important to note that this is a bibliometric analysis and does not provide clinical evidence regarding the efficacy or safety of SCFAs in treating cognitive impairment.

How this fits prior evidence

This bibliometric analysis identifies emerging research frontiers in gut-brain axis interactions and neuroinflammation. While it maps the growing volume of literature on short-chain fatty acids, it does not provide clinical data to confirm or contrast with existing findings such as the role of HMGCR as a potential target in Alzheimer's disease or the impact of exercise training on hippocampal neurogenesis.

Researchers looked at hundreds of scientific papers to see how scientists are studying short-chain fatty acids (SCFAs). These are natural substances produced in the gut. The study found that interest in how these compounds affect memory and brain health has grown steadily every year since 2009.

Many experts are now focusing on the link between the gut and the brain. They use specific terms like 'gut-brain axis' and 'neuroinflammation' to describe how your digestive system might influence your mental clarity. This area of study is becoming a major focus for those trying to understand memory loss.

While this report does not prove that these compounds can treat diseases, it shows where the most active research is happening. It identifies key experts and centers that are leading the way in studying how gut health impacts the brain. This map helps other scientists know where to focus their future work.

What this means for you:
Research into how gut-produced fatty acids affect brain health is growing rapidly and becoming a major scientific focus.

Common questions

What are short-chain fatty acids?

Short-chain fatty acids (SCFAs) are compounds that researchers are studying because of their potential role in the gut-brain axis. This study tracked how research on these specific substances has grown steadily from 2009 to 2025.

Does this mean these treatments work for Alzheimer's?

This study does not provide clinical evidence that short-chain fatty acids treat or cure any condition. It is a bibliometric analysis, which means it tracks the amount of research being published by scientists rather than testing medicine on patients.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
ObjectiveShort-chain fatty acids (SCFAs) have been widely investigated in research related to cognitive impairment, yet systematic bibliometric analyses focusing on their correlation remain relatively scarce. This study employed bibliometric analysis to objectively review relevant literature, identify key research contributors, and uncover emerging frontiers in the field.MethodsRelevant literature published from 2009 to 2025 was retrieved from the Web of Science Core Collection (WoSCC) and Scopus databases. Bibliometric analyses were performed using the Bibliometrix R package, VOSviewer, and CiteSpace software to evaluate research outputs and generate visualizations.ResultsA total of 425 eligible articles from WoSCC and 514 from Scopus were included. Annual publications on SCFAs and cognitive impairment showed a continuous upward trend from 2009 to 2025. China contributed the largest number of publications in this field, and an international collaboration network has been established, with Wenzhou Medical University (China) serving as the core collaboration hub. International Journal of Molecular Sciences was identified as a major publication platform, and Zhang, Xin was recognized as a core author in SCFA-cognitive impairment research. High-frequency keywords included “gut microbiota,” “Alzheimer’s disease,” “neuroinflammation,” and “gut-brain axis.” In addition, recent research frontiers encompassed “drug therapy,” “microbiology,” and “chemistry,” revealing the core themes and trends of SCFA and cognitive impairment studies.ConclusionThis study conducted a comprehensive bibliometric analysis of the association between SCFAs and cognitive impairment, clarified the evolutionary trajectory of research themes, and identified potential future research directions. It revealed a developmental pattern whereby research in this field has gradually advanced from exploring basic correlations between diet and gut microbiota to in-depth investigations of pathological mechanisms, precise targeted interventions, and clinical translational applications. By systematically depicting the current research landscape, this study aims to provide guidance for subsequent investigations and fill critical knowledge gaps.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.